US index futures fell over 4% early this morning, erasing most of yesterday’s gain. Crude oil might be a drag on broad sentiment, as US WTI slid further into the $26.8 area.
A deeply imbalanced supply and demand outlook has not changed as Saudi and Russia have ramped up production in a time when global energy demand is badly hurt by border controls and travel bans. The situation may not change any time soon. WTI may hover around $28 for a while and it may head south if more restrictions are implemented worldwide.
US markets rebounded overnight on stimulus hopes that could amount to an $850 billion spending package. Meanwhile, the Federal Reserve announced plans to enter the commercial paper market to provide an extra $500 billion liquidity to support overnight lending. This underscores the fragility of the short-term debt market and stretch in liquidity. Again, the core issue is to contain Covid-19’s spread and prevent systemic risk.
According to a recent report from IHS Markit, US GDP is set to fall by 5.4% annualised rate in the second quarter. A recession could last until the end of the year.
Is there any game changer? Yes, there might be one. China has announced a start to human trials on an experimental coronavirus vaccine conducted by China’s Academy of Military Medical Sciences last night. A clinically approved Covid-19 vaccine might hopefully bring a silver lining to this chaotic market.
Asia Pacific markets are seeking stability today striking a balance between the virus impact and stimulus hopes. Greater China markets may prove to be more resilient against external shocks, as the mainland is the first major economy to recover from the Covid-19 outbreak. Business activity has gradually recovered in most areas outside of Hubei Province, albeit a foreseeable decline in external demand is going to weigh on growth throughout the year.
Disclaimer: CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.
CMC Markets Singapore may provide or make available research analysis or reports prepared or issued by entities within the CMC Markets group of companies, located and regulated under the laws in a foreign jurisdictions, in accordance with regulation 32C of the Financial Advisers Regulations. Where such information is issued or promulgated to a person who is not an accredited investor, expert investor or institutional investor, CMC Markets Singapore accepts legal responsibility for the contents of the analysis or report, to the extent required by law. Recipients of such information who are resident in Singapore may contact CMC Markets Singapore on 1800 559 6000 for any matters arising from or in connection with the information.
Margaret Yang Yan